Oral GLP-1s
This page contains affiliate links. We may earn a commission if you sign up through them, at no cost to you. All recommendations are independent.
August 18, 2026 · Oral GLP-1 editorial specialty

The Complete 2026 Oral GLP-1 Landscape: Every Product Available and Where

The oral GLP-1 category has matured into a genuine alternative to injectable therapy in 2026. Here's the complete map of what's available, from brand-name FDA-approved products to compounded specialty formulations.

The Brand-Name Oral Products

Rybelsus (oral semaglutide) has been FDA-approved for type 2 diabetes since 2019. Wegovy pill (higher-dose oral semaglutide) received weight-management approval in late 2025 and has been commercially available through 2026. These represent the current FDA-approved oral GLP-1 landscape.

Rybelsus at diabetes doses (3, 7, 14 mg) has established evidence for glycemic control. Wegovy pill at weight-management doses (up to 25 mg) has established weight-loss data from the OASIS trial program.

The Compounded Oral Category

Compounded oral semaglutide and tirzepatide are available through pharmacy-direct and telehealth-bundled channels. Formats include orally disintegrating tablets (ODTs), sublingual troches, and oral drops. Pricing generally runs $99-$229 depending on molecule, dose, and format.

Compounded oral tirzepatide has stronger regulatory footing than compounded oral semaglutide because no brand-name oral tirzepatide exists to compete with — the Section 503A "meaningful difference" standard is easier to meet.

MadeMed

Compounded oral tirzepatide ~$167–$229/mo

Independent compounder — oral tirzepatide specialty.

  • Compounded oral tirzepatide
  • $167–$229 range by dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

The Emerging Products

Orforglipron — a non-peptide oral GLP-1 agonist from Eli Lilly — is progressing through late-stage clinical trials with potential FDA approval anticipated in the coming years. It represents a mechanistic novelty: unlike Rybelsus and Wegovy pill (which are peptide semaglutide with absorption enhancers), orforglipron is a small molecule GLP-1 agonist that doesn't have the same absorption constraints.

The Category Positioning

Oral GLP-1s aren't equivalent substitutes for injectable in efficacy terms — injectable typically produces slightly greater weight loss at equivalent-effect doses. But for many patients, the format advantages (no needles, no cold storage, discreet dosing) matter more than a small efficacy gap. Oral has become a genuine category, not just a compromise.

Telos Rx

$365 CPA — compounded pathway

Compounded GLP-1 via direct pharmacy program.

  • Compounded GLP-1 focus
  • Direct-link intake format
  • Verify pricing at intake
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

How to Choose Within the Category

Rybelsus fits type 2 diabetes patients wanting oral GLP-1. Wegovy pill fits weight-management patients wanting brand-name oral. Compounded oral semaglutide fits patients wanting oral at lower cost than brand-name pill. Compounded oral tirzepatide fits patients wanting oral tirzepatide specifically (no brand equivalent exists). Format decision often comes down to insurance coverage, cost tolerance, and molecule preference.

MadeMed

Compounded oral tirzepatide ~$167–$229/mo

Independent compounder — oral tirzepatide specialty.

  • Compounded oral tirzepatide
  • $167–$229 range by dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

Telos Rx

$365 CPA — compounded pathway

Compounded GLP-1 via direct pharmacy program.

  • Compounded GLP-1 focus
  • Direct-link intake format
  • Verify pricing at intake
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

Where to Start

MadeMed

Compounded oral tirzepatide ~$167–$229/mo

Independent compounder — oral tirzepatide specialty.

  • Compounded oral tirzepatide
  • $167–$229 range by dose tier
  • Direct pharmacy fulfillment
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing

Telos Rx

$365 CPA — compounded pathway

Compounded GLP-1 via direct pharmacy program.

  • Compounded GLP-1 focus
  • Direct-link intake format
  • Verify pricing at intake
FDA note: Compounded GLP-1 medications are not FDA-approved. Personalization must be based on a documented clinical need per current FDA guidance.
Check Latest Pricing
Medical & editorial disclaimer. This article is for informational purposes only and is not medical advice. GLP-1 medications require prescriber evaluation. Compounded GLP-1 medications are not FDA-approved. Talk to a licensed clinician before starting, stopping, or changing any prescription. Provider pricing, availability, and program terms change frequently — verify current details on each provider's site before making a decision. Some links are affiliate links, which means we may earn a commission if you sign up; this does not change our recommendations or the price you pay.